The signaling pathway induced by anti-CD40, as we reported with normal B cells (3) is distinct from and synergistic with anti-CD20 mAbs like rituximab, and can promote increased lymphoma cell death (47–49). This evidence concerns the gene MS4A1 and lymphoma.